Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,725 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,608 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07672223 | A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 3 | 570 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Jun 26, 2026 | clinicaltrials |
| NCT02220894 | Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | completed | Phase 3 | 1,274 | Merck Sharp & Dohme LLCINDUSTRY |
| 0 |
| Jun 25, 2026 |
| clinicaltrials |
| NCT03088540 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 712 | Regeneron PharmaceuticalsINDUSTRY | 24 | Jun 25, 2026 | clinicaltrials |
| NCT06216301 | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC(LUNAR-2) | recruiting | Phase 3 | 734 | NovoCure GmbHINDUSTRY | 16 | Jun 25, 2026 | clinicaltrials |
| NCT07131319 | SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC | recruiting | Phase 2 / Phase 3 | 30 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT00324805 | Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery | completed | Phase 3 | 1,501 | National Cancer Institute (NCI)NIH | 5 | Jun 23, 2026 | clinicaltrials |
| NCT00693992 | Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy | completed | Phase 3 | 210 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05555732 | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) | active not recruiting | Phase 3 | 1,170 | Daiichi SankyoINDUSTRY | 29 | Jun 23, 2026 | clinicaltrials |
| NCT05059522 | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | active not recruiting | Phase 3 | 77 | PfizerINDUSTRY | 19 | Jun 22, 2026 | clinicaltrials |
| NCT07524257 | Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC | withdrawn | Phase 3 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07660094 | Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)(LuTK03) | recruiting | Phase 3 | 500 | Candel Therapeutics, Inc.INDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04475939 | Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer(ZEAL-1L) | completed | Phase 3 | 666 | GlaxoSmithKlineINDUSTRY | 27 | Jun 18, 2026 | clinicaltrials |
| NCT05221840 | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer(PACIFIC-9) | active not recruiting | Phase 3 | 1,051 | AstraZenecaINDUSTRY | 20 | Jun 18, 2026 | clinicaltrials |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects(CANOPY-1) | terminated | Phase 3 | 673 | Novartis PharmaceuticalsINDUSTRY | 41 | Jun 17, 2026 | clinicaltrials |
| NCT07473128 | Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer | recruiting | Phase 3 | 120 | Pharmacosmos A/SINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06031558 | Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC | active not recruiting | Phase 3 | 120 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07416994 | Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 3 | 440 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04155034 | S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer | active not recruiting | Phase 3 | 668 | SWOG Cancer Research NetworkNETWORK | 7 | Jun 11, 2026 | clinicaltrials |
| NCT04214262 | Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 415 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07633873 | SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） | not yet recruiting | Phase 3 | 500 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Jun 11, 2026 | clinicaltrials |
| NCT06267001 | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy(SKYSCRAPER-15) | terminated | Phase 3 | 56 | Hoffmann-La RocheINDUSTRY | 11 | Jun 10, 2026 | clinicaltrials |
| NCT02785952 | Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | active not recruiting | Phase 3 | 275 | SWOG Cancer Research NetworkNETWORK | 2 | Jun 9, 2026 | clinicaltrials |
| NCT03306992 | Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study(PEP) | completed | Phase 3 | 182 | University of UtahOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03637335 | Comparing Palliative Radiotherapy With or Without Carboplatin(METAXIOM) | terminated | Phase 3 | 26 | Institut Cancerologie de l'OuestOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07636226 | QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07637513 | Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer(PrE0512) | not yet recruiting | Phase 3 | 430 | PrECOG, LLC.OTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT01993810 | Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer | active not recruiting | Phase 3 | 330 | Radiation Therapy Oncology GroupNETWORK | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04513925 | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)(SKYSCRAPER-03) | completed | Phase 3 | 829 | Hoffmann-La RocheINDUSTRY | 26 | Jun 3, 2026 | clinicaltrials |
| NCT04619797 | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer(SKYSCRAPER-06) | completed | Phase 2 / Phase 3 | 542 | Hoffmann-La RocheINDUSTRY | 21 | Jun 3, 2026 | clinicaltrials |
| NCT05549037 | Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC(LungTIME-C01) | completed | Phase 3 | 210 | Hunan Province Tumor HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT01687647 | Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure(AMORCE-CBP) | terminated | Phase 3 | 463 | University Hospital, CaenOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT02075840 | A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants(ALEX) | completed | Phase 3 | 303 | Hoffmann-La RocheINDUSTRY | 29 | May 29, 2026 | clinicaltrials |
| NCT02688036 | Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC | completed | Phase 3 | 860 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07608159 | Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC. | not yet recruiting | Phase 3 | 201 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | May 29, 2026 | clinicaltrials |
| NCT05015608 | Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification(SACHI) | completed | Phase 3 | 216 | Hutchison Medipharma LimitedINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT03520686 | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | terminated | Phase 3 | 102 | ImmunityBio, Inc.INDUSTRY | 1 | May 26, 2026 | clinicaltrials |
| NCT05668988 | A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) | active not recruiting | Phase 3 | 324 | Dizal PharmaceuticalsINDUSTRY | 15 | May 26, 2026 | clinicaltrials |
| NCT04841811 | MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)(APPROACH) | active not recruiting | Phase 3 | 192 | Guangdong Association of Clinical TrialsOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06616532 | PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer | active not recruiting | Phase 3 | 404 | Biotheus Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT04768075 | Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC | completed | Phase 3 | 60 | Guangdong Association of Clinical TrialsOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02504489 | Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC(DUBLIN-3) | completed | Phase 3 | 559 | BeyondSpring Pharmaceuticals Inc.INDUSTRY | 3 | May 19, 2026 | clinicaltrials |
| NCT06127654 | Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy(VITaL) | recruiting | Phase 3 | 165 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07154706 | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | recruiting | Phase 3 | 180 | Nuvation Bio Inc.INDUSTRY | 3 | May 19, 2026 | clinicaltrials |
| NCT02438722 | S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 174 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT03409614 | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 789 | Regeneron PharmaceuticalsINDUSTRY | 18 | May 18, 2026 | clinicaltrials |
| NCT03851445 | Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 10,000 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT05096663 | Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 / Phase 3 | 82 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 26, 2026source: clinicaltrials